ACADIA Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 6/6
ACADIA Pharmaceuticals ha un patrimonio netto totale di $577.2M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $976.9M e $399.7M. L'EBIT di ACADIA Pharmaceuticals è $112.2M rendendo il suo rapporto di copertura degli interessi -4.8. Ha liquidità e investimenti a breve termine pari a $565.3M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
US$0
Debito
| Indice di copertura degli interessi | -4.8x |
| Contanti | US$565.33m |
| Patrimonio netto | US$577.18m |
| Totale passività | US$399.69m |
| Totale attività | US$976.87m |
Aggiornamenti recenti sulla salute finanziaria
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $788.3M ) di ACAD superano le sue passività a breve termine ( $343.9M ).
Passività a lungo termine: Le attività a breve termine di ACAD ( $788.3M ) superano le sue passività a lungo termine ( $55.7M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: ACAD è esente da debiti.
Riduzione del debito: ACAD non ha avuto debiti negli ultimi 5 anni.
Copertura del debito: ACAD non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.
Copertura degli interessi: ACAD non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.